Author(s): Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ni Luh Putu Yunia Dewi, Putu Gita Raditya Sanjiwani, Ni Nyoman Gita Kharisma Dewi, Dwijo Anargha Sindhughosa, I Ketut Mariadi

Email(s): mariadi@unud.ac.id

DOI: 10.52711/0974-360X.2025.00004   

Address: Kadek Mercu Narapati Pamungkas1, Putu Itta Sandi Lesmana Dewi1, Ni Luh Putu Yunia Dewi1, Putu Gita Raditya Sanjiwani2, Ni Nyoman Gita Kharisma Dewi1, Dwijo Anargha Sindhughosa1,3, I Ketut Mariadi1,4*
1Centre Research for Alimentary and Hepatobiliary System, Denpasar, Bali, Indonesia. 2Faculty of Medicine of Udayana University, Denpasar, Bali, Indonesia.
3Division of Gastroenterology and Hepatology, Department of Internal Medicine, Udayana University, Bali, Indonesia.
4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Udayana University/ Ngoerah Hospital, Bali, Indonesia.
*Corresponding Author

Published In:   Volume - 18,      Issue - 1,     Year - 2025


ABSTRACT:
Introduction: The escalating use of opioids in the management of cancer-induced pain has become notably prevalent. However, the prolonged use of opioids frequently gives rise to constipation. The primary approach to managing constipation involves the administration of oral laxatives with a combination of stool softeners, serving as the first-line therapeutic modalities. However, in individuals with chronic opioid use, leading to persistent constipation, reliance on laxatives may prove inadequate. Methods: We searched literature from Pubmed, CENTRAL, Science Direct, and Google Scholar from January 2013 to September 2023. Relevant studies on the use of methylnaltrexone to treat OIC in cancer patients were collected. The random effect model was used in this study to evaluate size effects. Result: This study included six studies involving 1044 cancer patients with OIC. Methylnaltrexone increased laxations compared to placebo after 4 hours after the first dose in RCTs (OR 8.96, 95% CI 3.68 - 21.81, p < 0.00001). Cohort studies using proportional analysis found that the pooled rate was 71% (n= 2 studies, 95% CI 0.54 - 0.88). Methylnaltrexone also increased adverse events compared to placebo in RCTs (OR 2.48, 95% CI 1.24 - 4.98, p = 0.01). A pooled rate of 19% of adverse events in methylnaltrexone groups (n = 3 studies, 95% CI 0.00-0.43). Abdominal discomfort, gas accumulation, and feelings of nausea emerged as the top adverse events reported in RCTs. There were no significant differences in the change of baseline pain score after 4 hours of the first dose in both study groups. Also, there were no significant differences after 7 days post-dose in cancer patients (p = 0.704). Conclusion: Despite the adverse events, Methylnaltrexone significantly triggered bowel movements within 4 hours after the first dose, compared to the placebo. Methylnaltrexone did not inhibit analgesic actions. Thus, it does not interfere main treatment for cancer pain.


Cite this article:
Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ni Luh Putu Yunia Dewi, Putu Gita Raditya Sanjiwani, Ni Nyoman Gita Kharisma Dewi, Dwijo Anargha Sindhughosa, I Ketut Mariadi. The Efficacy and Safety of Methylnaltrexone in Cancer patients with Opioid-induced Constipation: A Systematic Review and Meta-analysis. Research Journal of Pharmacy and Technology. 2025;18(1):24-2. doi: 10.52711/0974-360X.2025.00004

Cite(Electronic):
Kadek Mercu Narapati Pamungkas, Putu Itta Sandi Lesmana Dewi, Ni Luh Putu Yunia Dewi, Putu Gita Raditya Sanjiwani, Ni Nyoman Gita Kharisma Dewi, Dwijo Anargha Sindhughosa, I Ketut Mariadi. The Efficacy and Safety of Methylnaltrexone in Cancer patients with Opioid-induced Constipation: A Systematic Review and Meta-analysis. Research Journal of Pharmacy and Technology. 2025;18(1):24-2. doi: 10.52711/0974-360X.2025.00004   Available on: https://rjptonline.org/AbstractView.aspx?PID=2025-18-1-4


REFERENCES:
1.    Jamshed N, Lee ZE, Olden KW. Diagnostic approach to chronic constipation in adults. Am Fam Physician. 2011; Aug 1; 84(3): 299-306. PMID: 21842777.
2.    Chapman CR, Lipschitz DL, Angst MS, Chou R, Denisco RC, Donaldson GW, et al. Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence base. J Pain. 2010; 11(9): 807–829. doi:10.1016/j.jpain.2010.02.019
3.    Manchikanti L, Vallejo R, Manchikanti KN, Benyamin RM, Datta S, Christo PJ. Effectiveness of long-term opioid therapy for chronic non-cancer pain. Pain Physician. 2011; 14(2): E133–156. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21412378. Accessed October 13, 2014.
4.    Anonim. Opioid Painkiller Prescribing. Vital Signs, Centers Dis Control Prev. 2014. Available at: http://www.cdc.gov/vitalsigns/opioid-prescribing/. Accessed October 9, 2023.
5.    Ramachandram DS, Chitra V, Rini R. Current Opioid Access, Use and Problems in Asian Jurisdictions. Research Jour of Pharm and Technol. 2020; 13(4): 1991.
6.    Thapa D, Rastogi V, Ahuja V. Cancer pain management-current status. J Anaesthesiol Clin Pharmacol. 2011; 27(2): 162–168.
7.    Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DA, Webster LR, Becker G. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. J Clin Gastroenterol. 2015; Jan; 49(1): 9-16. doi: 10.1097/MCG.0000000000000246.
8.    Kalso E, Edwards JE, Moore AR, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004 Dec;112(3):372-380. doi: 10.1016/j.pain.2004.09.019.
9.    Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 2009; 10(1): 35–42. doi:10.1111/j.1526-4637.2008.00495.x
10.    Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001; 93(3): 247–257. doi:10.1016/S0304-3959(01)00324-4
11.    Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181–1187. doi:10.1111/j.1742-1241.2007.01415.x
12.    Weschules DJ, Bain KT, Reifsnyder J, McMath JA, Kupperman DE, Gallagher RM, et al. Toward evidence-based prescribing at end of life: a comparative analysis of sustained-release morphine, oxycodone, and transdermal fentanyl, with pain, constipation, and caregiver interaction outcomes in hospice patients. Pain Med. 2006; Jul-Aug; 7(4): 320-9. doi: 10.1111/j.1526-4637.2006.00184.x.
13.    Kumar L, Barker C, Emmanuel A. Opioid-induced constipation: pathophysiology, clinical consequences, and management. Gastroenterol Res Pract. 2014; 2014: 141737. doi: 10.1155/2014/141737.
14.    Nelson AD, Camilleri M. Chronic opioid-induced constipation in patients with nonmalignant pain: challenges and opportunities. Therap Adv Gastroenterol. 2015; 8(4): 206–220. doi:10.1177/1756283X15578608.
15.    Lennon FE, Mirzapoiazova T, Mambetsariev B, Poroyko VA, Salgia R, Moss J, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; Mar 24; 9(3): e91577. doi: 10.1371/journal.pone.0091577.
16.    Singleton PA, Moss J, Karp DD, Atkins JT, Janku F. The mu opioid receptor: a new target for cancer therapy? Cancer. 2015; 121(16): 2681–2688. doi:10.1002/cncr.29460.
17.    Zylla D, Steele G, Shapiro A, Richter S, Gupta P. Impact of opioid use on health care utilization and survival in patients with newly diagnosed stage IV malignancies. Support Care Cancer. 2018; 26(7): 2259–2266. doi:10.1007/s00520-018-4062-z.
18.    Slatkin N, Thomas J, Lipman AG, Wilson G, Boatwright ML, Wellman C, et al. Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients. J Support Oncol. 2009; Jan-Feb; 7(1): 39-46. PMID: 19278178.
19.    Yuan CS, Foss JF, O’Connor M, Toledano A, Roizen MF, Moss J. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther. 1996; 59(4): 469–475. doi:10.1016/S0009- 9236(96)90117-4.
20.    Galligan JJ, Akbarali HI. Molecular physiology of enteric opioid receptors. Am J Gastroenterol Suppl. 2014; 2(1): 17–21. doi:10.1038/ajgsup.2014.5
21.    Wickham RJ. Managing constipation in adults with cancer. J Adv Pract Oncol. 2017; 8(2): 149–161.
22.    Emmanuel A, Johnson M, McSkimming P, Dickerson S. Laxatives do not improve symptoms of opioid-induced constipation: results of a patient survey. Pain Med. 2017; 18(10): 1932–1940. doi:10.1093/pm/pnw240
23.    Bader S, Jaroslawski K, Blum HE, Becker G. Opioid-induced constipation in advanced illness: safety and efficacy of methylnaltrexone bromide. Clin Med Insights Oncol. 2011; 5: 201–211. doi:10.4137/CMO.S4867.
24.    Michna E, Blonsky ER, Schulman S, Tzanis E, Manley A, Zhang H, et al. Subcutaneous methylnaltrexone for treatment of opioid-induced constipation in patients with chronic, nonmalignant pain: A Randomized Controlled Study. J Pain. 2011; 12(5): 554–562. doi:10.1016/j.jpain.2010.11.008.
25.    Salix Pharmaceuticals. Relistor [Package Insert]. Bridgewater, NJ: Salix Pharmaceuticals; 2020. Available at https://www.relistorhcp.com/tablet-dosing, accessed October 9, 2023
26.    Thomas J, Karver S, Cooney GA, Chamberlain BH, Watt CK, Slatkin NE, et al. Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med. 2008; May 29; 358(22): 2332-43. doi: 10.1056/NEJMoa0707377.
27.    Mori M, Ji Y, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study. Int J Clin Oncol. 2017; Apr; 22(2): 397-404. doi: 10.1007/s10147-016-1041-6.
28.    Nelson KK, Schattner MA, Mendelsohn RB. Methylnaltrexone is safe in cancer patients with peritoneal carcinomatosis. Sci Rep. 2019; Jul 3; 9(1): 9625. doi: 10.1038/s41598-019-44864-2.
29.    Rodrigues A, Wong C, Mattiussi A, Alexander S, Lau E, Dupuis LL. Methylnaltrexone for opioid-induced constipation in pediatric oncology patients. Pediatr Blood Cancer. 2013; Oct; 60(10): 1667-70. doi: 10.1002/pbc.24615.
30.    Nalamachu SR, Pergolizzi J, Taylor R Jr, Slatkin NE, Barrett AC, Yu J, et al. Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials. Pain Pract. 2015; Jul;15(6): 564-71. doi: 10.1111/papr.12218.
31.    Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. Methylnaltrexone Treatment for Opioid-Induced Constipation in Patients with and without Cancer: Effect of Initial Dose. J Pain Res. 2023; Jul 27; 16: 2595-2607. doi: 10.2147/JPR.S405825.
32.    Chamberlain BH, Rhiner M, Slatkin NE, Stambler N, Israel RJ. Subcutaneous Methylnaltrexone for Treatment of Opioid-Induced Constipation in Cancer versus Noncancer Patients: An Analysis of Efficacy and Safety Variables from Two Studies. J Pain Res. 2021; Sep 1; 14: 2687-2697. doi: 10.2147/JPR.S312731.
33.    Janku F, Johnson LK, Karp DD, Atkins JT, Singleton PA, Moss J. Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancer. Ann Oncol. 2016; Nov; 27(11): 2032-2038. doi: 10.1093/annonc/mdw317.
34.    Gnanarani JJ, Venkatesan L. The Palliative Care Needs, Quality Of Life and Coping Strategies among Oncology Patients And End Stage Organ Disease. Asia Jour Nurs Educ and Rese. 2016; 6(3): 371.
35.    Bang HY, Yeun EJ, Kim HJ. The Quality of Life and Fatigue of Gastric Cancer Patients. Rese Jour of Pharm and Technol. 2019; 12(7): 3289.
36.    Sampoornam W. Stress and Quality of Life among Breast Cancer Patients. Asian J. Nur. Edu. and Research. 2014; 4(3): 325-327
37.    Kaur J. An Exploratory Study to Assess the Quality of Life among Cancer Patients of District Bathinda, Punjab. Asia Jour Nurs Educ and Rese. 2015; 5(1): 18.
38.    Chellappan S, Rajkumar R, Jeyapal M. Cancer Pain Management: Teaching Program for Terminally ill Cancer Patients. Asia Jour Nurs Educ and Rese. 2017; 7(2): 151.
39.    Rallabhandi S, Chakole V, Singam A. Comparison of Transdermal Fentanyl Patch and Intravenous Fentanyl for Postoperative pain relief in patients undergoing major abdominal surgeries under general Anaesthesia. Research J. Pharm. and Tech. 2021; Apr 29; 1915–8.
40.    Dharma P, Kumar S, Sagar MK. Development and Characterization of Transdermal patches of Tramadol Hydrochloride: An Approach to Pain Management. Research Journal of Pharmacy and Technology. 2022; 15(1): 1-5.
41.    Pati NB, Jyothi TS, Thakur GS, Reddy S, Meghna G. Tapentadol in Cancer Pain. Asia Journ of Resear in Pharmac Scie. 2017; 7(4): 183.
42.    Hamdan SJ, Al-Rawaq KJ, Razaq AA. Effect of Palliative Radiotherapy in controlling pain of Malignancy. RJPT. 2021; Nov 30; 5733–8.
43.    Rahmadi M, Iqbal Z, Pratama IN, Karunia RA, Puspitasari DA, Nisak K, et al. PEG-4000 Ameliorates morphine-induced constipation in mice through inhibition of AQP-3 mRNA Expression. Research Journal of Pharmacy and Technology. 2023; 16(7): 3331-8.
44.    Portenoy RK, Thomas J, Moehl Boatwright ML, Tran D, Galasso FL, Stambler N, et al. Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study. J Pain Symptom Manage. 2008; May; 35(5): 458-68. doi: 10.1016/j.jpainsymman.2007.12.005.
45.    Bull J, Wellman CV, Israel RJ, Barrett AC, Paterson C, Forbes WP. Fixed-Dose Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: Results of a Randomized, Placebo-Controlled Study and Open-Label Extension. J Palliat Med. 2015; Jul; 18(7): 593-600. doi: 10.1089/jpm.2014.0362.
46.    Thomas J, Lipman A, Slatkin N, Wilson G, Moehl M, Wellman C, et al. A phase III double-blind placebo-controlled trial of methylnaltrexone (MNTX) for opioid-induced constipation (OIC) in advanced medical illness. J Clin Oncol. 2005; 23: 16S. Abstract. doi: 10.1200/jco.2005.23.16_suppl.lba8003
47.    Bhagat V, Menon S. The Efficacy of Using Hypnosis to Reduce Anxiety and Pain in Obstetrics and Gynecology Patients. Research J. of Pharm and Tech. 2020; 13(1): 347.


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank

Journal Policies & Information


Recent Articles




Tags


Not Available